The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide
Introduction. The new selective inhibitor of PAR-2 receptors, 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazole-5-carboxamide (R004), is at the stage of preclinical trail. The excretion of R004 and its metabolites has not been studied before.Aim....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2025-06-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/2054 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850047019575410688 |
|---|---|
| author | I. I. Yaichkov M. K. Korsakov N. N. Volkhin V. E. Zaykova O. E. Lasaraynz |
| author_facet | I. I. Yaichkov M. K. Korsakov N. N. Volkhin V. E. Zaykova O. E. Lasaraynz |
| author_sort | I. I. Yaichkov |
| collection | DOAJ |
| description | Introduction. The new selective inhibitor of PAR-2 receptors, 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazole-5-carboxamide (R004), is at the stage of preclinical trail. The excretion of R004 and its metabolites has not been studied before.Aim. Investigation of excretion of R004 and its metabolites in urine and feces after a single oral and intraperitoneal administration of substance.Materials and methods. The study was carried out on 2 groups of 6 Wistar rats. The R004 substance was administered orally to the first group at a dosage of 10 mg/kg, to the second group intraperitoneally at a dosage of 10 mg/kg. Biomaterial sampling was carried out with using metabolic cages. Urine was collected before administration of the drug and in the intervals of 0–4, 4–8, 8–12, 12–24, 24–48, 48–72, 72–96, 96–120 h after administration. Feces were collected before administration of the drug and in the intervals of 0–12, 12–24, 24–48, 48–72, 72–96, 96–120 h. The samples were analyzed using HPLC-MS/MS.Results and discussion. The analytical range of the urine quantification method for R004 and 4-methoxy-3-(trifluoromethyl) aniline (М2) was 5–2000 ng/ml, and 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-4,5-dihydro-1,2-oxazole-5-carboxylic acid (M1) – 100–40 000 ng/ml. In feces concentrations of R004 were measured in the range of 0.5–500.0 µg/g, M1 – 4–4000 ng/g, M2 – 40–40 000 ng/g. The main part of the drug and metabolites was excreted within 48 h after administration. Complete elimination was achieved after 96 h. R004 is excreted unchanged only with feces: 94.83 ± 0.78 % after oral administration and 67.04 ± 0.59 % after intraperitoneal administration (M + m). The metabolite M1 is mainly excreted by renal route, the metabolite M2 is mainly excreted through intestine.Conclusion. Bioanalytical methods for determination of R004, M1 and M2 in urine and feces have been successfully validated. Most part of the R004 is eliminated unchanged by enteric route. M1 is excreted mainly in urine, M2 – mainly in feces. |
| format | Article |
| id | doaj-art-76b405caf5634b9bab2c1cc965bf0c8e |
| institution | DOAJ |
| issn | 2305-2066 2658-5049 |
| language | Russian |
| publishDate | 2025-06-01 |
| publisher | LLC Center of Pharmaceutical Analytics (LLC «CPHA») |
| record_format | Article |
| series | Разработка и регистрация лекарственных средств |
| spelling | doaj-art-76b405caf5634b9bab2c1cc965bf0c8e2025-08-20T02:54:19ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492025-06-0114219320310.33380/2305-2066-2025-14-2-19161347The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamideI. I. Yaichkov0M. K. Korsakov1N. N. Volkhin2V. E. Zaykova3O. E. Lasaraynz4Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian Federation; Yaroslavl State Pedagogical University named after K. D. Ushinsky. M. V. Dorogov Pharmaceutical Technology Transfer CenterYaroslavl State Pedagogical University named after K. D. Ushinsky. M. V. Dorogov Pharmaceutical Technology Transfer CenterFederal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian FederationFederal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian Federation; Yaroslavl State Pedagogical University named after K. D. Ushinsky. M. V. Dorogov Pharmaceutical Technology Transfer CenterFederal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian Federation; Yaroslavl State Pedagogical University named after K. D. Ushinsky. M. V. Dorogov Pharmaceutical Technology Transfer CenterIntroduction. The new selective inhibitor of PAR-2 receptors, 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazole-5-carboxamide (R004), is at the stage of preclinical trail. The excretion of R004 and its metabolites has not been studied before.Aim. Investigation of excretion of R004 and its metabolites in urine and feces after a single oral and intraperitoneal administration of substance.Materials and methods. The study was carried out on 2 groups of 6 Wistar rats. The R004 substance was administered orally to the first group at a dosage of 10 mg/kg, to the second group intraperitoneally at a dosage of 10 mg/kg. Biomaterial sampling was carried out with using metabolic cages. Urine was collected before administration of the drug and in the intervals of 0–4, 4–8, 8–12, 12–24, 24–48, 48–72, 72–96, 96–120 h after administration. Feces were collected before administration of the drug and in the intervals of 0–12, 12–24, 24–48, 48–72, 72–96, 96–120 h. The samples were analyzed using HPLC-MS/MS.Results and discussion. The analytical range of the urine quantification method for R004 and 4-methoxy-3-(trifluoromethyl) aniline (М2) was 5–2000 ng/ml, and 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-4,5-dihydro-1,2-oxazole-5-carboxylic acid (M1) – 100–40 000 ng/ml. In feces concentrations of R004 were measured in the range of 0.5–500.0 µg/g, M1 – 4–4000 ng/g, M2 – 40–40 000 ng/g. The main part of the drug and metabolites was excreted within 48 h after administration. Complete elimination was achieved after 96 h. R004 is excreted unchanged only with feces: 94.83 ± 0.78 % after oral administration and 67.04 ± 0.59 % after intraperitoneal administration (M + m). The metabolite M1 is mainly excreted by renal route, the metabolite M2 is mainly excreted through intestine.Conclusion. Bioanalytical methods for determination of R004, M1 and M2 in urine and feces have been successfully validated. Most part of the R004 is eliminated unchanged by enteric route. M1 is excreted mainly in urine, M2 – mainly in feces.https://www.pharmjournal.ru/jour/article/view/2054par-2 receptor inhibitorhplc-ms/msvalidationpharmacokineticsexcretionurinefecesrats |
| spellingShingle | I. I. Yaichkov M. K. Korsakov N. N. Volkhin V. E. Zaykova O. E. Lasaraynz The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide Разработка и регистрация лекарственных средств par-2 receptor inhibitor hplc-ms/ms validation pharmacokinetics excretion urine feces rats |
| title | The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide |
| title_full | The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide |
| title_fullStr | The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide |
| title_full_unstemmed | The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide |
| title_short | The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide |
| title_sort | excretion study of a new derivative of 4 5 dihydroisoxazole 5 carboxamide |
| topic | par-2 receptor inhibitor hplc-ms/ms validation pharmacokinetics excretion urine feces rats |
| url | https://www.pharmjournal.ru/jour/article/view/2054 |
| work_keys_str_mv | AT iiyaichkov theexcretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT mkkorsakov theexcretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT nnvolkhin theexcretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT vezaykova theexcretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT oelasaraynz theexcretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT iiyaichkov excretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT mkkorsakov excretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT nnvolkhin excretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT vezaykova excretionstudyofanewderivativeof45dihydroisoxazole5carboxamide AT oelasaraynz excretionstudyofanewderivativeof45dihydroisoxazole5carboxamide |